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ABSTRACT
To best of authors knowledge, this article presents the first-ever non-invasive glucometer that takes
into account serum glucose for high accuracy. In case of blood glucose measurement, serum glucose
value has always been considered precise blood glucose value during prandial modes. Serum glucose
can be measured in laboratory and more stable glucose level compare to capillary glucose. However,
this invasive approach is not convenient for frequent measurement. Sometimes, Conventional
invasive blood glucose measurement may be responsible for cause of trauma and chance of blood
related infections. To overcome this issue, in the current paper, we propose a novel Internet-of-
Medical (IoMT) enabled glucometer for non-invasive precise serum glucose measurement. In this
work, a near-infrared (NIR) spectroscopic technique has been used for glucose measurement. The
novel device called iGLU 2.0 is based on optical detection and precise machine learning (ML)
regression models. The optimal multiple polynomial regression and deep neural network models
have been presented to analyze the precise measurement. The glucose values of serum are saved
on cloud through open IoT platform for endocrinologist at remote location. To validate iGLU 2.0,
Mean Absolute Relative Difference (mARD) and Average Error (AvgE) are obtained 6.07% and
6.09%, respectively from predicted blood glucose values for capillary glucose. For serum glucose,
mARD and AvgE are found 4.86% and 4.88%, respectively. These results represent that proposed
non-invasive glucose measurement device is more precise for serum glucose compared to capillary
glucose.
Keywords Smart healthcare, Healthcare Cyber-Physical System (CPS), Internet-of-Medical-Things (IoMT),
Continous glucose measurement, Non-invasive glucose measurement, Capillary glucoes, Serum glucose, Regression
model, Kernel based calibration
1 Introduction
Remote connectivity of doctors and patients is the key solution in providing better and advanced medical facilities
to the patients [1, 2]. As the healthcare technologies are being advanced, there is an increment and consciousness
of consumers for their health. In particular scenario, the demand for remote healthcare is more promoted than
ever. Present Internet-of-Medical-Things (IoMT) solution for smart healthcare encourages hospitals to ameliorate
the care quality with focusing on overall expenses reduction. The basic requirement of our Smart Healthcare solution
comprises of sensors that collect patient data, cloud to store, analyze and process the data, web services and mobile
applications for patients and doctors. In a big picture IoMT enabled healthcare Cyber-Physical System (CPS) makes
smart healthcare possible [3].
The non-invasive, precise and rapid diagnosis of diabetes is of great demand worldwide due to low-cost, painless, and
easy of usage [4, 5, 6, 7]. Instant non-invasive serum glucose measurement is not being possible at present to overcome
the cause of trauma. Hence, the instant measurement of serum glucose with continuous monitoring is being recent
challenge in the smart healthcare system. Proposed serum glucose measurement device is a handheld, IoMT enabled
end-device which provides rapid and continuous monitoring. It interacts with an endocrinologist to the remote located
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diabetic patients. The process flow of blood glucose diagnosis in smart health care system is shown in Figure 1, which
represents the smart healthcare system for diabetic patients at remote location.
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Figure 1: Blood glucose diagnosis in smart health care system.
In proposed non-invasive serum glucose measurement, optical detection approach is involved. The collected data is
processed for acquisition and glucose is predicted by the regression model. The process flow is shown in Figure 2.
According to this process, patients measure their serum glucose without pricking blood and store directly to the cloud
where nearby endocrinologist can analyze the serum glucose data of particular patient. The prescription would also be
sent by endocrinologist to particular patient for further treatment. Traditionally, blood glucose is being measured in
the form of serum and capillary glucose of diabetic patients. The serum glucose test is a laboratory test where serum
(centrifuged blood) is extracted from blood to measure the glucose level, whereas capillary glucose is being measured
by commercially available glucometer. In this process, a drop of blood is pricked through lancet from finger and
blood drop is taken on strip which has to be connected to the glucometer. For accurate blood glucose value, diabetic
patients are always recommended for the serum glucose test. But, the whole process takes 1-2 hours for serum glucose
value. Hence, it is necessary to develop the device which can measure the serum glucose without puncturing the finger
instantly. People will be more conscious for blood glucose continuous monitoring. Such a device is advisable for
smart healthcare. Designing a non-invasive serum glucose monitoring device comprises of spectroscopy techniques.
Spectroscopy is the interaction between optical radiation and any molecules. This technique is used to measure the
resultant light after interaction with molecules at the specific resonance frequency.
The rest of the paper is composed in the following manner. The prior related work is described in Section 2. Novel
contribution of this paper is represented in Section 3. Section 4 discusses analytical modelling and calibration details
of the sensor for serum and capillary glucose. The proposed device is presented with mechanism of serum glucose
detection in Section 5. Experiments and analytical modelling with error analysis have been elaborated in Section 6.
2 The State-of-Art in Glucose Measurement and its Advancement through the Current
Paper
2.1 Prior Research on Glucose Level Monitoring
Research on glucose level monitoring is being undertaken for a long time and also ongoing. Related prior research
work can be classified as invasive, minimally invasive, and non-invasive blood glucose monitoring as represented in
Figure 3.
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Figure 2: Processing steps of non invasive blood glucose measurement device.
Various invasive and non-invasive approaches have been explored for glucose measurement [8]. Demitri, et al.
represented the photometric approach for glucose measurement using small blood volumes [9]. To mitigate the issue
of frequent pricking blood, one-time wearable sensor is proposed in terms of a semi-invasive approach. This wearable
sensor has advantages of rapid diagnosis and continuous monitoring. But, this has to be changed after a certain period.
Hence, this will be irritating and may be the cause of trauma. Wang, et al. represented wearable minimally invasive
microsystem for glucose monitoring [7]. This wearable microsystem is a neither painless nor cost-effective solution.
Acciaroli, et al. discussed the new method to reduce the frequency of calibration of minimally invasive Dexcom sensor
[10]. To make the painless system, Pai, et al. designed the prototype setup of photoacoustic spectroscopy for non-
invasive glucose measurement [11]. But, implementation of corresponding components yield the setup costly and also
occupies large area. However, the solution will not be portable. Yin, et al. proposed a DiabDeep framework that merge
wearable sensors and neural networks for pervasive diagnosis of diabetes. They achieved classification accuracy to
classify the healthy and diabetic patients. They considered various environmental and physiological parameters to
justify the diabetic patients. However, accuracy has not been identified in terms of blood glucose measurement [12].
The work did not represent any kind of error analysis. Prasad, et. al. presented nanoparticles on alkali anodized steel
(AS) electrode for glucose measurement through saliva [13]. Singh, et al. represented optical biosensor for glucose
measurement using saliva [14]. Glucose measurement has also been done using IMPS spectroscopy through the skin
[15, 16]. Electrical properties of skin, sweat and saliva vary according to person. So, this approach will not be reliable
for glucose measurement. Non-invasive glucose measurement approach through retina has also been represented for
precise glucose detection [17]. Such non-invasive approach is not desirable for frequent monitoring [18]. Raman
spectroscopy has been preented for precise glucose measurement [19]. The implemented setup occupied a large area
and will not be portable.
2.2 Commercial Products on Glucose Level Monitoring
Various products such as glucometer from Labiotech [20], GlucoTrack R©, and so on have limitations in terms of
precision. The cost of these products is also high which varies in the range of 300-400 USD. Therefore, the
cost effective device for precise non-invasive blood glucose measurement is presented. The Medical Training
Initiative (MTI) is developing a non-invasive glucose monitoring device glucowise
TM
. 2M Engineering is also actively
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Figure 3: An overview of the related prior works.
developing solution for non-invasive glucose monitoring [21]. The device is based on Raman scattering spectroscopy
technique with the use of laser technology. However, this is not cost effective solution. These devices are not available
in the market for medication. In this way Freestyle Libre sensor, SugarBEAT from Nemaura medical are available in
the market for medication [22]. These products are adhesive and skin-patch which are regularly disposable. These
devices support the continuous glucose monitoring. These are minimally invasive devices. Omelon B-2 is one of
the non-invasive stripless devices for continuous glucose monitoring which is available in the market for medication
[23]. The device is bulky and is not wearable device for continuous glucose level monitoring and the precision in
measurement has also not been achieved according to the users remarks.
2.3 Why NIR over other Non-Invasive Approaches?
Glucose measurement has been done using various non-invasive approaches such as impedance spectroscopy, NIR
light spectroscopy, PPG signal analysis and so on. But, apart from optical detection, other techniques have constraints
in terms of precise measurement. Desirable accuracy is not possible from measurement through sweat and saliva as
properties always vary for each person. PPG signal analysis is based on extracted features of logged signal which is
not based on principle of glucose molecular detection [24, 25]. The methodology of glucose measurement through
PPG signal and NIRS are represented in Figure 4.
To overcome these limitations, Sharma, et al. also discussed about optical detection using long NIR wave which is
not capable to detect the glucose molecules beneath the skin as it has shallow penetration [26]. Therefore, small NIR
wave has been chosen for real-time glucose detection [27, 28].
2.4 Why Serum Glucose over Capillary Glucose?
In the case of invasive approaches, serum glucose and capillary glucose level are being analyzed for precise blood
glucose values. Capillary glucose can be estimated instantly but serum glucose couldn’t be identified instantly due
to certain processes. However, it is clinically observed that the capillary glucose level is always higher than serum
glucose which is not being considered actual blood glucose ever. Hence, there is a trade-off between both approaches.
But, serum glucose has always been recommended for diagnosis as an accuracy point of view. Therefore, serum
glucose is always being reliable compared to capillary glucose for medication.
The serum glucose measurement is explored through NIR light as presented in Figure 5. The incident light is passed
through blood vessels and blood glucose molecules are detected in flowing concentration. During capillary glucose
measurement, the drop of blood is pricked from epidermis layer of skin. The precise value of glucose may not be
possible always through capillary blood glucose measurement. Therefore, serum glucose measurement is advisable
through diabetologist generally for precise measurement.
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Figure 4: Mechanism of Serum and Capillary Glucose Measurement.
Blood in Vessel
NIR LED NIR Detector Voltage Acquisition 
through  Light Detection 
from Blood Vessels 
Optical Spectroscopy for 
Serum Glucose Measurement
Pricking of the 
Blood
Contact to strip 
for Monitoring
Capillary Glucose
Measurement
Blood Pricking from 
Epidermis Layer of Skin 
Figure 5: NIR Spectroscopy Mechanism of Serum Glucose Measurement.
2.5 Advancement over our Previous work iGLU
The works related to non-invasive blood glucose measurement have been proposed using multiple techniques. Non-
invasive detection reduces the chance of being blood-related infections during measurement. But, these measurement
techniques have some limitations. Hence, the device iGLU 1.0 has been represented for non-invasive capillary glucose
measurement [4]. Serum glucose has always been considered more precise compared to capillary blood glucose as
per medical aspects. Therefore, it is required to design a portable device for non-invasive serum glucose measurement
which would have better accuracy. In current paper, iGLU 2.0 is proposed for serum glucose monitoring using short-
wave NIR spectroscopy technique with calibration and validation [29].
3 Novel Contributions of the Current Paper to the State-of-Art
Research Questions Addressed in the current Paper: For serum glucose measurement, it is necessary to prick the
blood and it takes more time to measure the glucose. The well equipped laboratory is required for processes to extract
the serum and storage at specific (frozen) temperature. Hence, the laboratory needs a large space with frozen facility
of serum. Hence, this process is neither being a cost-effective nor time-saving solution in terms of instant diagnosis.
The questions which are addressed in the current paper for the advancement of smart healthcare: (1) How can we have
a device that can measure serum glucose without pricking the blood at the user and stores the data in cloud for future
use by the patient and healthcare providers? (2) Can we have a device that can provide the facility of continuous serum
glucose monitoring at the user-end so that it can function even if the Internet connectivity is not available all the time?
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(3) Can we have a device that can measure automatically serum glucose frequently all the time? (4) Can we have a
device that can measure the serum glucose of all types of patients precisely?
Challenges in Addressing the Research Problem and Questions: The solution of various challenges for the research
questions to obtain precise serum glucose measurement include the following: (1) Analyzing and validation of specific
wavelengths for glucose detection are required for precise measurement. (2) Optimization in circuit level design of
data acquisition module is required to improve the performance of proposed device for CGM. (3) Acquiring of voltages
and serially transfer for data logging will be possible with synchronization for frequent measurement. (4) Analysis
of optimized regression model with calibration and validation using healthy and diabetic samples to measure serum
glucose of all patients precisely.
Proposed Solution of this Paper: To address the above research questions, we proposed an edge-device called iGLU
2.0 in the current paper that measures serum glucose of patient and stores the data at the cloud. We have proposed
the non-invasive serum glucose measurement device which is a comparatively precise and low-cost solution. The
proposed device is also integrated with IoMT framework for data storage on the cloud. The risk factor of blood-related
diseases has been mitigated through proposed device. The device can be used to measure the serum glucose of every
person at anytime. iGLU 2.0 is an advancement in the non-invasive device era. This device measures the serum
glucose instantly with continuous monitoring. Flow of proposed work is represented in Figure 6.
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Figure 6: Top level representation of proposed device (iGLU 2.0).
Novel contribution in current paper include the following:
1. A precise non-invasive serum glucometer called iGLU 2.0 using absorption and reflectance of light with two
short NIR waves using specific wavelengths (940 nm and 1300 nm) has been introduced.
2. An optimized kernel based regression model for serum glucose sensor calibration has been presented.
3. A serum glucose monitoring device has been formed with optimized circuital biasing of sensors for calibration
using precise and optimized regression model to validate and test the subjects.
4. With the active support from diabetic center and hospital, real-life experimental validation has been done
directly from human blood.
5. The proposed device has been integrated in IoMT framework for data (serum glucose values) storage, patient
monitoring and treatment on proper time with cloud access by both the patient and doctor.
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4 Machine Learning (ML)Models for BloodGlucose Level Calculation from the NIR Signal
Optimized computation model is analyzed after calibration of regression models (RM) for serum and capillary glucose
estimation. In current work, the detector’s outputs from three channels are logged as input vectors for prediction of
glucose. The calibrated models are used to predict the blood glucose concentrations for validation. The logged data
from each sample is essential to convert in predicted glucose values. Hence, it is required to calibrate an appropriate
kernel for precise measurement. 113 samples of capillary glucose and 74 samples of serum glucose are taken for device
calibration which includes prediabetic, diabetic and healthy samples. The baseline characteristics of the samples are
shown in Table 1.
Table 1: Baseline characteristics of collected samples for calibration, validation and testing.
Samples Basic Capillary Serum Capillary Serum
Characteristics Glucose Glucose Glucose Glucose
Calibration Validation and Testing
Age (Years) Prediabetic Samples
Male:-18-80 Male:-23 Male:-13 Male:-18 Male:-10
Female:-17-75 Female:-20 Female:-16 Female:-16 Female:-09
Age (Years) Diabetic Samples
Male:-18-80 Male:-30 Male:-18 Male:-14 Male:-15
Female:-17-75 Female:-19 Female:-12 Female:-12 Female:-12
Age (Years) Healthy Samples
Male:-18-80 Male:-09 Male:-08 Male:-07 Male:-05
Female:-17-75 Female:-12 Female:-07 Female:-07 Female:-08
Age (Years) Total Samples
Male:-18-80 Male:-62 Male:-39 Male:-39 Male:-30
Female:-17-75 Female:-51 Female:-35 Female:-35 Female:-29
The proposed process flow of calibration and validation is shown in Figure 7. Mean absolute deviation (MAD), AvgE,
mARD, and Root Mean Square Error (RMSE) are calculated to analyze the performance of proposed device.
4.1 Proposed Deep Neural Network (DNN) and Other Models for Glucose Sensor Calibration
Several machine learning-based computation models have been examined to get optimized regression method in terms
of precise measurement. Support vector regression with multiple Gaussian kernels is used to analyze the optimized
model. In case of blood glucose estimation, a margin of tolerance (epsilon) is set in approximation as per the
independent variables. To reduce the error, a kernel (medium gaussian kernel) scale value is also set to the square
root of number of predictors. This customized kernel scale is used to remove the outlier from data. The cubic kernel
(kernel with polynomial degree 3) based model is customized to remove the outliers. This customized kernel scale is
used for precise measurement. Kernel (fine gaussian kernel) scale value is also set to the square root of predictors which
is divided by 4 (
√
P
4 ). The fitting model of DNN has also been analyzed for capillary and serum glucose prediction
in the current work [16]. Sigmoid activation functions have been used in the proposed DNN models and have been
trained through Levenberg-Marquardt backpropagation algorithm [30]. In proposed models, 10 hidden layers have
been analyzed to predict precise glucose values. The error analysis is graphically represented in Figure 8. These
optimized models have been used to predict the glucose values from logged data. Here, the responses (voltages) from
three channels are taken as inputs of the proposed DNN models. The predicted blood glucose values corresponding
to capillary and serum glucose are formed through the modelling of three channels voltage values. Weights of the
voltage values correlate predicted glucose values to the channels data. Overall accuracy through DNN is better using
10 hidden layers. The block diagram of DNN model is given in Figure 9.
4.2 Proposed Method: Multiple Polynomial Regression (MPR) model of Glucose Concentration with Voltage
Multiple polynomial regression with polynomial degree 3 based model (MPR 3) is applied to analyze the optimized
model for capillary and serum glucose prediction. Using multiple polynomial regression, proposed model represents
the relationship between three channels detector’s outputs and corresponding referenced glucose values (serum glucose
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Figure 7: The process flow of calibration and validation of proposed device (iGLU 2.0).
or capillary glucose) by fitting a cubic kernel based regression model which is represented as follows:
y = a1x
3
1 + a2x
3
2 + a3x
3
3 + a4x
2
1x2 + a5x
2
1x3 + a6x1x
2
2 + a7x1x
2
3 + a8x
2
2x3
+a9x2x
2
3 + a10x
2
1 + a11x
2
2 + a12x
2
3 + a13x1x2x3 + a14x1x2 + a15x1x3
+a16x2x3 + a17x1 + a18x2 + a19x3 + , (1)
where, a1-a19 are regression coefficients and  is residual of errors. The model is used to observe the predicted
glucose value from iGLU. The values of these regression coefficients and residual of error depend upon the predictors
and corresponding response of calibrated model. In the proposed model, three channels voltage values are represented
as x1, x2 and x3 as independent variables (predictors) and estimated glucose (mg/dl) is the dependent variable y. Each
value of detector’s output voltage value is associated with reference glucose value. Proposed multiple polynomial
regression model (MPR 3) kernel for calibration is represented in Figure 10.
Proposed MPR is a complex multivariable interaction approach based regression model. 19 customized interacted
variables combinations based kernel is an optimized model which is represented in eq. 10. The maximum polynomial
degree 3 of terms (interactions of multiple variables) have been analyzed for precise model. The correlation plots
between predicted glucose concentration and reference glucose concentration for regression models are represented in
Figure 11(a)- Figure 11(h). The error analysis of calibrated machine learning regression models is also represented in
Table 2.
Proposed MPR 3 model represents better results of calibration and validation compared to DNN based model and
other regression models because of its complexity and polynomial interaction-based approach with polynomial degree
3. During analysis, prediction of serum glucose is found more precise compared to prediction of capillary glucose
using MPR 3.
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Figure 9: The Deep Neural Network (DNN) for proposed work
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Table 2: Statistical Analysis of calibration of proposed model and existing techniques.
Regression mARD AvgE MAD RMSE
Model % % mg/dl mg/dl
Linear SVR (Capillary) 34.40 31.27 65.64 83.50
Serum 39.24 36.21 70.59 83.21
Cubic SVR (Capillary) 31.85 27.32 59.42 79.66
Serum 26.69 32.55 51.92 73.32
Quadratic SVR (Capillary) 33.43 29.73 63.59 81.38
Serum 33.42 10.86 61.35 83.47
Medium Gaussian SVR (Capillary) 31.36 26.82 58.43 77.83
Serum 26.50 24.66 47.75 66.01
Coarse Gaussian SVR (Capillary) 33.71 30.74 64.58 82.10
Serum 40.09 34.75 70.37 81.05
Fine Gaussian SVR (Capillary) 14.31 12.49 27.36 45.06
Serum 12.31 10.45 20.96 31.09
DNN (Capillary) 29.06 22.14 46.47 62.51
Serum 9.11 8.95 19.47 27.95
MPR3 (Capillary) 6.07 6.09 13.28 19.71
Serum 4.86 4.88 9.42 13.57
5 Design of the Proposed Novel Glucometer for Serum Glucose Monitoring - The iGLU 2.0
The proposed device is based on short wave NIR spectroscopy using wavelengths (940 and 1300 nm) and implemented
using three channels. Each channel contains emitter and detector of a particular wavelength for glucose detection. The
flow of proposed work is represented in Figure 6.
5.1 The Proposed Approach for Data Acquisition
The pseudocode of data acquisition for proposed iGLU 2.0 is represented in process flow which is shown in Figure
12. The data is collected and serially logged by 16 bit ADC with sample rate of 128 samples/sec. The logged data is
calibrated and validated through an optimized model of existing regression techniques for precise measurement.
Independent samples of person aged 24-50 have also been taken for testing and validation of iGLU 2.0. The serum
glucose values have been stored on the cloud using open IoT platform. The data can be accessed by patients and
doctor. On the basis of serum glucose values, the treatment can be provided at a remote location. A 2 layer PCB is
designed and system is developed to embed NIR LEDs and detectors.
The circuit is designed to implement the setup for optical detection [4]. Emitters, detectors and ADS 1115 are
embedded with optimized biasing with 5 V DC supply. Passive components have been chosen for better efficiency
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Figure 11: Correlation plot of predicted and referenced blood glucose concentration model during calibration.Page – 11-of-19
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Figure 12: Process flow data acquisition for proposed device (iGLU 2.0).
of NIR LEDs and detectors. All NIR LEDs and detectors are connected with proper biasing. The detectors are used
in photoconductive mode. All detectors have specifications of daylight blocking filters [4]. ADS 1115 has been used
to serially transferred the three channels data in decimal form. The ADS 1115 is controlled through microcontroller
ATmega328P using arduino uno board.
5.2 The Proposed System of the Glucometer
In this paper, we implement optical detections using specific wavelengths for absorptions and reflection. Concentration
of glucose molecules depends upon the change in light intensity. The logged voltage values from the detectors depend
on received light intensity. During placing the object (fingertip or earlobe) between NIR LED and detector, the voltages
(data) are logged. The coherent averaging of voltage samples is done to improve the measurement error. For calibration
and validation, the averaging of 1024 samples has been done in 8 seconds. Block representation of proposed iGLU
is shown in Figure 13. During experimental analysis, serum glucose has been measured in laboratory and capillary
glucose has been measured by invasive glucometer SD check gold device for validation [31]. The serum and capillary
glucose values are taken as referenced glucose values (mg/dl). At that time, detector responses (in milivolts) have
been collected through all channels simultaneously. During measurement process, the data has been logged through
all channels in the form of voltages from detector of each channel using ADS 1115. These logged voltage values are
corresponding to serum and capillary glucose values.
6 Validation of the Proposed Device iGLU 2.0
6.1 Testing and Error Analysis
After calibration of iGLU 2.0, 50 different healthy, prediabetic and diabetic samples of capillary glucose and 37
samples of serum glucose have been taken to validate the device. During device validation, 26 males and 20 females
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Figure 13: Block Representation of proposed device (iGLU 2.0).
samples are tested following medical protocols. The samples are taken in fasting, post-prandial and random modes for
validation and testing. The baseline characteristics and error analysis is represented in Table 1 and 3.
Table 3: Statistical Analysis of validation of proposed model and existing techniques.
Regression mARD AvgE MAD RMSE
Model % % mg/dl mg/dl
FGSVR (Capillary) 14.09 11.45 25.20 41.18
Serum 9.17 9.12 19.09 27.34
DNN (Capillary) 23.19 22.14 45.07 59.74
Serum 11.67 10.02 21.81 34.05
MPR3 (Capillary) 7.74 7.70 16.08 22.46
Serum 5.009 4.97 9.74 12.98
As per analysis of results, serum glucose measurement is found more accurate compared to capillary glucose
measurement using MPR 3 model. To test the device stability, an experimental analysis has been done with multiple
measurements of 2 volunteers. For this experimental work, each volunteer has been chosen for measurement of
capilary and serum glucose through iGLU 2.0. The measurement has been done in fasting and post-prandial mode.
Result analysis is shown in Figure 15.
6.2 Clarke Error Grid (CEG) Analysis
CEG analysis is explored by W. L. Clarke in 1970. This is used to analyze the accuracy of predicted blood glucose
concentration values from proposed device. This error analysis has been presented to analyze the precision level of
predicted blood glucose values from device iGLU 2.0 [32]. Clarke analysis explores the zones by the variation between
referenced and predicted glucose concentration. All samples have been arranged gender-wise to confirm the accuracy
of iGLU 2.0 for capillary and serum glucose measurement along with testing and validation which are represented in
Figure 16 and 17 respectively. The proposed device is considered as desirable for clinical purpose. According to Table
4, proposed non-invasive device iGLU 2.0 is more precise compared to other glucose monitoring devices. During
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Figure 15: Predicted and reference blood glucose concentration for validation of iGLU 2.0 on 2 volunteers.
analysis, it has been observed that all samples of serum glucose exist in zone A and all samples of capillary glucose
exist in zone A and zone B.
It has also been concluded that 4.86% mARD of serum glucose is better than 6.07% mARD of capillary glucose.
The AvgE and MAD 4.88% and 9.42 mg/dl represent the precision level of the proposed device. Real-time analysis
and cross validation have been performed for real-time applications [5].
7 Conclusions and Future Directions of This Research
Non-invasive serum glucose measurement device is proposed which is based on short-wave NIR spectroscopy with
two specific wavelengths (940 and 1300 nm). The device is validated and tested through healthy, prediabetic and
diabetic patients. The combination of reflection and absorption of NIR light using MPR model based calibration
is implemented for non-invasive serum glucose measurement. The proposed device is the combination of optical
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(b) Male samples of serum glucose
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(c) Female samples of capillary glucose
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(d) Female samples of serum glucose samples
Figure 16: CEG analysis of predicted blood glucose concentration for validation of iGLU 2.0 device.
detection and optimized machine earning regression model which is an innovative approach for precise serum glucose
measurement. For device validation, all samples have been taken from persons aged 17-80. During device calibration
for serum glucose, the capillary glucose has also been calculated from the same samples for error analysis. During
statistical analysis, 0.79 coefficient of determination is calculated for serum glucose calibration using MPR based
model with polynomial degree 3 which shows a better result compared to capillary glucose calibration. It has been
observed that AvgE and mARD represent better results of calibration and validation for serum glucose compared to
capillary glucose. After analysis of predicted serum glucose values, 100% samples come in zone A.
In the future research, we will consider Internet-of-Medical-Things (IoMT) integration of the iGLU in healthcare CPS
(H-CPS) so that the healthcare data can be securely stored in the cloud. We will also evaluate the options of edge-
computing and IoT-computing paradigms for fast response as well as long-term storage of the user’s records. This can
be have significant impact on smart living component of smart healthcare for smart homes [33]. The long-term goal of
iGLU project is an unified H-CPS for non-invasive glucose level monitoring and release of appropriate level of insulin
with full-proof security arrangement [34].
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(a) Validation samples of capillary glucose
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(b) Validation samples of serum glucose
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(c) Testing samples of capillary glucose
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(d) Testing samples of serum glucose samples
Figure 17: CEG analysis of predicted blood glucose concentration for validation of iGLU 2.0 device.
Table 4: Comparison with Non-invasive Works
Works R mARD AvgE MAD RMSE Used Measurement Device
value (%) (%) (mg/dl) (mg/dl) model sample cost
Singh, et al. [14] 0.80 - - - - Human Saliva Cheaper
Song, et al. [16] - 8.3 19 - - Human Blood Cheaper
Pai, et al. [11] - 7.01 - 5.23 7.64 in-vitro Blood Costly
Dai, et al. [15] - 5.99 5.58 - - in-vivo Blood Cheaper
Beach, et al. [8] - - 7.33 - - in-vitro Solution -
Ali, et al. [27] - 8.0 - - - Human Blood Cheaper
Haxha, et al. [28] 0.96 - - - 33.49 Human Blood Cheaper
Jain, et al. (iGLU) [4] 0.95 6.65 7.30 12.67 21.95 Human Blood Cheaper
Proposed Work (iGLU 2.0) 0.97 4.86 4.88 9.42 13.57 Human Blood Cheaper
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